Jiangsu (SH:688426) Zheng Quan Zhi Xing·2025-08-29 17:11Core Viewpoint - Jiangsu Kangwei Century Biotechnology Co., Ltd. has conducted its second board meeting, approving several key proposals related to its 2025 semi-annual report, fundraising, project completion, and governance changes, reflecting a commitment to transparency and operational efficiency [1][2][3]. Group 1: Financial Reporting and Fund Management - The board approved the 2025 semi-annual report, confirming compliance with relevant laws and regulations, and asserting that the report accurately reflects the company's financial status and operational results [1]. - The board also approved a special report on the storage and use of raised funds, indicating that the funds have been stored in dedicated accounts and used as intended, with no violations reported [2]. - A proposal to permanently supplement working capital with surplus funds from a completed project was approved, with 10,478.54 million yuan being reallocated for this purpose [3]. Group 2: Operational Efficiency and Governance - The company has actively implemented measures from its 2025 quality improvement and efficiency enhancement plan, focusing on core business, customer expansion, and increased R&D investment [4]. - A proposal to cancel the supervisory board and amend the company’s articles of association was approved, transferring supervisory responsibilities to the audit committee of the board [6]. - The board approved the revision and establishment of several internal governance systems to align with updated regulations and improve operational compliance [7]. Group 3: Shareholder Engagement and Future Meetings - The board proposed to hold the first extraordinary general meeting of 2025 on September 15, 2025, to discuss various matters, ensuring shareholder engagement in corporate governance [8]. - The board also approved the appointment of Yin Jianfeng as a member of the audit committee, enhancing the committee's operational capacity [9].